Single-use Bioreactors - Market Insights, Competitive Landscape, and Market Forecast - 2034

Single-use Bioreactors Market Summary

• The global Single-use bioreactors market is expected to increase from USD 3,613.82 million in 2025 to USD 15,114.53 million by 2034, reflecting strong and sustained growth.
• The global Single-use bioreactors market is growing at a CAGR of 17.27% during the forecast period from 2026 to 2034.
• The single-use bioreactors market is being strongly driven by the combined impact of rising demand for biopharmaceuticals, cost efficiency, and technological advancements in bioprocessing. The growing need for biologics such as monoclonal antibodies, vaccines, and cell & gene therapies is increasing the demand for flexible and sterile manufacturing platforms, where single-use systems are highly effective. At the same time, these bioreactors significantly reduce capital investment and operational costs by eliminating cleaning, sterilization, and large infrastructure requirements, making them especially attractive for emerging biotech firms and CDMOs. Additionally, continuous innovations in bioprocessing, such as improved scalability, automation, and advanced sensor integration, are enhancing productivity and process control. Together, these factors are accelerating the adoption of single-use bioreactors across R&D and commercial manufacturing, thereby boosting overall market growth.
• The leading companies operating in the single-use bioreactors market include Sartorius AG, Thermo Fisher Scientific Inc., Cytiva, Merck KGaA, Eppendorf SE, ABEC Inc., PBS Biotech Inc., Cellexus International Ltd., Celltainer Biotech BV, Getinge AB, Solaris Biotech Solutions S.r.l., Pierre Guerin SAS, Meissner Filtration Products Inc., Entegris Inc., Avantor Inc., Repligen Corporation, Corning Incorporated, and others.
• North America is expected to dominate the single-use bioreactors market due to its strong biopharmaceutical industry, high adoption of advanced bioprocessing technologies, and significant presence of key players such as Thermo Fisher Scientific Inc., Cytiva, and Sartorius AG. The region also benefits from substantial R&D investments, a well-established regulatory framework, and increasing demand for biologics, vaccines, and cell & gene therapies. Additionally, the growing number of CDMOs and biotechnology startups further accelerates the adoption of flexible and cost-effective single-use systems, supporting overall market growth.
• In the product type segment of the single-use bioreactors market, the single-use bioreactor system category is estimated to account for the largest market share in 2025.

Factors Contributing to the Growth of the Single-use Bioreactors Market

• Rising demand for biopharmaceuticals leading to a surge in single-use bioreactors: The increasing demand for biologics such as monoclonal antibodies, vaccines, recombinant proteins, and gene therapies is the primary driver of the SUB market. These therapies require flexible and sterile manufacturing systems, making single-use bioreactors highly suitable.
• Cost efficiency and lower capital investment: Single-use bioreactors significantly reduce overall costs by eliminating the need for expensive stainless-steel infrastructure, thereby lowering capital expenditure. They also remove the requirement for cleaning and sterilization processes, which reduces operational expenses related to labor, validation, and cleaning agents. In addition, utility costs such as water, steam, and energy consumption are minimized due to their disposable and pre-sterilized nature. Overall, these systems can lower initial investment by approximately 40% compared to traditional bioreactors, making them highly attractive for startups and contract development and manufacturing organizations (CDMOs) seeking cost-efficient and flexible production solutions.
• Technological advancements in bioprocessing: Continuous innovations in single-use bioreactors are significantly improving bioprocessing efficiency through advancements in large-scale bioreactor design, with systems now reaching capacities of 5000L and beyond. At the same time, the integration of automation and digital monitoring technologies allows for real-time data tracking and improved operational control. Enhanced sensor integration and advanced process control systems further ensure precise regulation of critical parameters such as pH, temperature, and dissolved oxygen. Together, these advancements lead to higher productivity, improved consistency in output, and greater scalability, making single-use bioreactors increasingly suitable for both clinical and commercial manufacturing.

Single-use Bioreactors Market Report Segmentation

This single-use bioreactors market report offers a comprehensive overview of the global single-use bioreactors market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Products Type (Single-use Bioreactor System { Up to 10 L, 11-100 L, 101-500 L, 501-1500 L, and Above 1500 L}, Single-use Media Bags {2D bags and 3D bags}, Single-use Filtration Assemblies, and Other Accessories), Type (Stirred-tank Single-use Bioreactors, Wave-induced (rocking motion) Bioreactors, and Others), Cell Type (Mammalian, Bacterial, and Others), Molecule Type (Monoclonal antibodies (mAbs), Vaccines, Recombinant Proteins, and Others), Application (Research & Development (R&D) and Bioproduction / Commercial Manufacturing), End-Users (Pharmaceutical & Biopharmaceutical Companies, Contract Research Organizations (CROs), Contract Development & Manufacturing Organizations (CDMOs/CMOs), and Academic & Research Institutes), and geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing Single-use Bioreactors market.

A single-use bioreactor (SUB) is a disposable bioprocessing system used to grow cells or microorganisms for the production of biologics such as vaccines, monoclonal antibodies, and recombinant proteins. Instead of traditional stainless-steel vessels, it uses pre-sterilized, single-use plastic bags, eliminating the need for cleaning and sterilization between batches. This makes single-use bioreactors more flexible, cost-effective, and efficient, particularly for research, process development, and small- to mid-scale biopharmaceutical manufacturing.

The single-use bioreactors market is being strongly driven by the combined impact of rising demand for biopharmaceuticals, cost efficiency, and continuous technological advancements in bioprocessing. The increasing need for biologics such as monoclonal antibodies, vaccines, recombinant proteins, and cell & gene therapies is significantly boosting the demand for flexible, scalable, and contamination-free manufacturing platforms, where single-use systems offer clear advantages over traditional stainless-steel setups. In addition, these bioreactors substantially reduce capital investment and operational costs by eliminating the need for complex infrastructure, cleaning validation, and sterilization processes, making them particularly attractive for emerging biotech companies, startups, and contract development and manufacturing organizations (CDMOs).

Furthermore, ongoing innovations in bioprocessing, such as the development of large-scale single-use systems (up to 5000L and beyond), integration of automation and digital monitoring, and advanced sensor technologies, are improving process efficiency, real-time control, and product consistency. These advancements also support faster turnaround times and greater manufacturing flexibility, enabling companies to respond quickly to changing market demands and accelerate time-to-market for new therapies. Collectively, these factors are driving widespread adoption of single-use bioreactors across research, clinical, and commercial production stages, thereby significantly boosting overall market growth.

What are the latest Single-use Bioreactors market dynamics and trends?

The rising demand for biopharmaceuticals, particularly monoclonal antibodies, vaccines, recombinant proteins, and advanced therapies such as cell and gene therapies, is one of the strongest drivers accelerating the growth of the single-use bioreactor (SUB) market. As biologics increasingly dominate modern drug pipelines due to their high specificity and efficacy, manufacturers require flexible, scalable, and contamination-free production systems, which single-use bioreactors efficiently provide. Unlike traditional stainless-steel systems, SUBs eliminate the need for cleaning and sterilization between batches, significantly reducing downtime, operational costs, and risk of cross-contamination, features that are especially critical in high-demand biologics manufacturing and small-batch personalized medicine. This shift is further reinforced by the rapid expansion of contract development and manufacturing organizations (CDMOs), which rely on SUBs to quickly scale production capacity in response to fluctuating biopharma demand.

Recent developments further highlight how rising biopharmaceutical demand is translating into technological expansion and product launches. For instance, in March 2025, Cytiva (Danaher) expanded its Xcellerex platform with large-scale 500 L and 2,000 L single-use bioreactors to support increasing monoclonal antibody and vaccine production needs.

Additionally, the growing focus on cost efficiency and lower capital investment is one of the most powerful drivers accelerating the adoption of single-use bioreactors (SUBs) in biopharmaceutical manufacturing. Traditional stainless-steel bioreactor facilities require heavy upfront investment for installation, infrastructure, cleaning systems, sterilization units, and validation processes. In contrast, single-use bioreactors use pre-sterilized disposable bags, eliminating the need for complex cleaning-in-place (CIP) and sterilization-in-place (SIP) systems. This significantly reduces initial capital expenditure (CAPEX) and also lowers operational expenditure (OPEX) related to water, energy, labor, and maintenance. Studies show that single-use-based facilities can reduce capital costs by nearly 40-50% compared to conventional stainless-steel plants, making them highly attractive for small and mid-sized biotech firms as well as contract development and manufacturing organizations (CDMOs). For instance, in April 2025, WuXi Biologics completed commercial-scale production campaigns using three 5,000 L single-use bioreactors, demonstrating how CDMOs are scaling capacity rapidly while avoiding massive capital investments in traditional facilities.

Thus, the factors mentioned above are expected to boost the overall market of single-use bioreactors during the forecast period.

However, plastic waste generation and environmental concerns, along with mechanical and operational limitations, collectively act as significant restraints for the single-use bioreactor market. The extensive use of disposable plastic bags and tubing leads to a growing volume of biomedical waste, raising sustainability issues and increasing disposal costs, especially as production scales up. At the same time, the mechanical fragility of single-use systems, such as sensitivity to pressure, mixing inefficiencies, and limited tolerance to shear stress, can restrict process optimization and scalability for certain high-demand or complex cell cultures. Together, these environmental and technical challenges limit full-scale adoption of single-use bioreactors in large, high-volume biomanufacturing facilities, where durability, efficiency, and sustainability are critical requirements.

Single-use Bioreactors Market Segment Analysis

Single-use Bioreactors Market by Products Type (Single-use Bioreactor System {Up to 10 L, 11-100 L, 101-500 L, 501-1500 L, and Above 1500 L}, Single-use Media Bags {2D bags and 3D bags}, Single-use Filtration Assemblies, and Other Accessories), Type (Stirred-tank Single-use Bioreactors, Wave-induced (rocking motion) Bioreactors, and Others), Cell Type (Mammalian, Bacterial, and Others), Molecule Type (Monoclonal antibodies (mAbs), Vaccines, Recombinant Proteins, and Others), Application (Research & Development (R&D) and Bioproduction / Commercial Manufacturing), End-Users (Pharmaceutical & Biopharmaceutical Companies, Contract Research Organizations (CROs), Contract Development & Manufacturing Organizations (CDMOs/CMOs), and Academic & Research Institutes), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Single-use Bioreactors Market Regional Analysis

North America Single-use Bioreactors Market Trends

North America is expected to account for the highest proportion of 34.75% of the single-use bioreactors market in 2025, out of all regions. North America is expected to dominate the single-use bioreactors market due to its strong biopharmaceutical industry, high adoption of advanced bioprocessing technologies, and significant presence of key players such as Thermo Fisher Scientific Inc., Cytiva, and Sartorius AG. The region also benefits from substantial R&D investments, a well-established regulatory framework, and increasing demand for biologics, vaccines, and cell & gene therapies. Additionally, the growing number of CDMOs and biotechnology startups further accelerates the adoption of flexible and cost-effective single-use systems, supporting overall market growth.

At the same time, technological innovations such as advanced stirred-tank designs, improved oxygen transfer systems, integrated sensors, and automation-enabled digital bioprocessing platforms are enhancing process efficiency, scalability, and product consistency, further driving adoption in the region. North America's leadership is reinforced by strong investments in biologics, vaccines, and cell and gene therapies, supported by major players like Thermo Fisher Scientific, Cytiva (Danaher), and Sartorius, expanding their single-use portfolios. For example, in 2025, Thermo Fisher introduced enhanced single-use bioreactor systems integrated with next-generation automation for improved scalability and productivity. In March 2025, Cytiva expanded its Xcellerex platform with higher-capacity single-use bioreactors to support flexible manufacturing needs across clinical and commercial production stages.

Thus, the factors mentioned above are expected to boost the overall market of single-use bioreactors across the region during the forecast period.

Europe Single-use Bioreactors Market Trends

The Single-use Bioreactors market in Europe is witnessing strong and sustained growth due to the region's well-established biopharmaceutical industry, increasing adoption of advanced biologics manufacturing technologies, and strong regulatory support for flexible and contamination-free production systems. European countries such as Germany, the UK, France, and Switzerland are major hubs for biologics, vaccines, and cell and gene therapy development, which is driving the rapid adoption of single-use technologies in both clinical and commercial manufacturing. The presence of leading companies like Sartorius, Merck KGaA, Cytiva, and Thermo Fisher Scientific further strengthens the regional ecosystem, as these players continuously introduce advanced stirred-tank and modular single-use bioreactor platforms to support scalable production. Additionally, Europe is experiencing growing demand for viral vector-based gene therapies and CAR-T cell therapies, where single-use bioreactors are preferred due to their closed-system design, reduced contamination risk, and faster batch turnaround times.

Recent developments further highlight this growth momentum. In 2023, the European Commission allocated €180 million under its Vector Manufacturing Initiative to expand GMP biomanufacturing capacity, explicitly supporting single-use platforms for viral vector and cell therapy production across the region.

Thus, the factors mentioned above are expected to boost the overall market of single-use bioreactors in Europe during the forecast period.

Asia-Pacific Single-use Bioreactors Market Trends

The Asia Pacific (APAC) region is emerging as a major growth driver for the single-use bioreactors market due to the rapid expansion of the biopharmaceutical industry, increasing government support for biotechnology development, and rising investments in biologics manufacturing infrastructure. Countries such as China, India, Japan, and South Korea are witnessing strong growth in vaccine production, monoclonal antibody development, and biosimilar manufacturing, all of which rely heavily on single-use bioreactor technologies for their flexibility, cost efficiency, and scalability. The region is also benefiting from the growing presence of contract development and manufacturing organizations (CDMOs), which are adopting single-use systems to meet global outsourcing demand for clinical and commercial biologics production. Additionally, favorable government initiatives promoting local vaccine manufacturing and biopharma self-sufficiency-especially after the COVID-19 pandemic-have significantly accelerated the adoption of advanced bioprocessing platforms.

Recent developments further highlight this momentum. In June 2024, WuXi Biologics expanded its single-use bioreactor capacity in China by adding multiple 5,000 L production lines, strengthening large-scale biologics manufacturing capabilities, and reinforcing demand for upstream single-use systems.

Thus, the factors mentioned above are expected to boost the overall market of single-use bioreactors across Europe during the forecast period.

Who are the major players in the single-use bioreactors market?

The following are the leading companies in the single-use bioreactors market. These companies collectively hold the largest market share and dictate industry trends.

• Sartorius AG
• Thermo Fisher Scientific Inc.
• Cytiva
• Merck KGaA
• Eppendorf SE
• ABEC Inc.
• PBS Biotech Inc.
• Cellexus International Ltd.
• Celltainer Biotech BV
• Getinge AB
• Solaris Biotech Solutions S.r.l.
• Pierre Guerin SAS
• Meissner Filtration Products Inc.
• Entegris Inc.
• Avantor Inc.
• Repligen Corporation
• Corning Incorporated
• Others

How is the competitive landscape shaping the single-use bioreactors market?

The competitive landscape of the single-use bioreactors market is becoming increasingly dynamic and consolidated, shaped by strong rivalry among a few global bioprocessing leaders and continuous technological innovation. Major players such as Thermo Fisher Scientific, Danaher (Cytiva), Sartorius AG, and Merck KGaA dominate the market through extensive product portfolios, global manufacturing networks, and continuous investment in next-generation bioreactor technologies. Competition is largely driven by the need to offer scalable, automated, and digitally integrated single-use systems that support faster biologics development and commercial production. Companies are increasingly focusing on strategic collaborations, mergers and acquisitions, and capacity expansions to strengthen their bioprocessing capabilities and expand geographic reach. For example, in 2025, Thermo Fisher Scientific expanded its bioprocessing ecosystem through major acquisitions and platform integration strategies to enhance upstream and downstream capabilities, while Cytiva and Sartorius continued to expand their stirred-tank and modular single-use bioreactor platforms in North America and Europe to support high-demand biologics production. At the same time, emerging players and regional manufacturers in the Asia Pacific are intensifying competition by offering cost-effective and customized solutions, particularly for CDMOs and local biopharma companies. This combination of technological innovation, strategic consolidation, and regional expansion is making the competitive landscape highly active, with companies focusing on improving efficiency, scalability, and end-to-end bioprocessing solutions to gain market advantage.

Recent Developmental Activities in the Single-use Bioreactors Market

• In February 2026, Thermo Fisher Scientific introduced the 5 L DynaDrive single-use bioreactor aimed at small-scale and academic GMP-ready bioprocessing, enabling broader access to biomanufacturing technologies.
• In April 2025, AGC Biologics announced an expansion of its Yokohama facility in Japan by installing two 5,000 L Thermo Scientific DynaDrive single-use bioreactors, enabling large-scale biologics production without the need for extensive stainless-steel infrastructure upgrades.
• In April 2025, WuXi Biologics completed commercial-scale production campaigns using three 5,000 L single-use bioreactors, demonstrating how CDMOs are scaling capacity rapidly while avoiding massive capital investments in traditional facilities.

Single-use Bioreactors Market Segmentation

• Single-use Bioreactors by Product Type Exposure
• Single-use Bioreactor Systems
• Up to 10 L
• 11-100 L
• 101-500 L
• 501-1500 L
• Above 1500 L
• Single-use Media Bags
• 2D bags
• 3D bags
• Single-use Filtration Assemblies
• Other Accessories
• Single-use Bioreactors Type Exposure
• Stirred-tank Single-use Bioreactors
• Wave-induced (rocking motion) Bioreactors
• Others
• Single-use Bioreactors Cell Type Exposure
• Mammalian
• Bacterial
• Others
• Single-use Bioreactors Molecule Type Exposure
• Monoclonal antibodies (mAbs)
• Vaccines
• Recombinant proteins
• Others
• Single-use Bioreactors Application Exposure
• Research & Development (R&D)
• Bioproduction / Commercial Manufacturing
• Single-use Bioreactors End-Users Exposure
• Pharmaceutical & biopharmaceutical companies
• Contract Research Organizations (CROs)
• Contract Development & Manufacturing Organizations (CDMOs/CMOs)
• Academic & Research Institutes
• Single-use Bioreactors Geography Exposure
• North America Single-use Bioreactors Market
• United States Single-use Bioreactors Market
• Canada Single-use Bioreactors Market
• Mexico Single-use Bioreactors Market
• Europe Single-use Bioreactors Market
• United Kingdom Single-use Bioreactors Market
• Germany Single-use Bioreactors Market
• France Single-use Bioreactors Market
• Italy Single-use Bioreactors Market
• Spain Single-use Bioreactors Market
• Rest of Europe Single-use Bioreactors Market
• Asia-Pacific Single-use Bioreactors Market
• China Single-use Bioreactors Market
• Japan Single-use Bioreactors Market
• India Single-use Bioreactors Market
• Australia Single-use Bioreactors Market
• South Korea Single-use Bioreactors Market
• Rest of Asia-Pacific Single-use Bioreactors Market
• Rest of the World Single-use Bioreactors Market
• South America Single-use Bioreactors Market
• Middle East Single-use Bioreactors Market
• Africa Single-use Bioreactors Market

Impact Analysis

AI-Powered Innovations and Applications:

AI-powered innovations are increasingly reshaping single-use bioreactors (SUBs) by making bioprocessing more predictive, automated, and efficient. Instead of relying only on manual monitoring and fixed process parameters, AI enables real-time decision-making, process optimization, and quality control across upstream biomanufacturing.

One major application is predictive process optimization, where machine learning models analyze historical and real-time bioprocess data (pH, dissolved oxygen, nutrient levels, and cell density) to predict optimal growth conditions and maximize yield of biologics such as monoclonal antibodies and vaccines. AI is also widely used in anomaly detection and contamination prediction, where algorithms continuously monitor sensor data to detect deviations early, reducing batch failure risks and improving product consistency. In advanced single-use systems, AI supports automated control loops, adjusting feeding rates, aeration, and temperature dynamically to maintain ideal cell culture conditions without human intervention.

Another key innovation is the integration of AI with digital twins of bioreactors, where a virtual model of the single-use system simulates cell culture behavior in real time. This helps scientists test different process conditions digitally before applying them physically, reducing development time and cost. Companies are also using AI for scale-up modeling, helping bridge the gap between laboratory-scale (e.g., 10-500 L) and commercial-scale bioreactors by predicting how cells will behave during scale transitions.

In addition, AI is enhancing process analytical technology (PAT) by interpreting complex multi-sensor data streams, enabling smarter feedback control systems in closed single-use bioreactor environments. This is particularly valuable in continuous and perfusion-based bioprocessing, where conditions must be tightly controlled over long production cycles.

Overall, AI is transforming single-use bioreactors into intelligent, self-optimizing biomanufacturing systems, improving productivity, reducing human error, lowering costs, and accelerating the development of next-generation biologics, vaccines, and cell and gene therapies.

U.S. Tariff Impact Analysis on Single-use Bioreactors Market:

The U.S. tariff impact analysis on the single-use bioreactors market indicates a moderate but strategically significant influence on pricing, supply chains, and manufacturing decisions rather than a direct demand reduction. Single-use bioreactors are classified under bioprocessing and medical/industrial equipment supply chains, many of which depend on imported components such as bioprocess bags, sensors, tubing systems, filters, and control systems, particularly from Europe and Asia. As a result, any U.S. tariff increases on medical devices, laboratory equipment, or industrial bioprocessing components can raise input costs for manufacturers operating in North America. This leads to higher production costs for single-use systems, increased pricing pressure on end users (biopharma companies and CDMOs), and potential short-term delays in procurement decisions. However, the impact is partially offset by the strong domestic manufacturing base in the U.S., where companies like Thermo Fisher Scientific, Cytiva (Danaher), and Merck have local production facilities, reducing reliance on imports. Additionally, tariffs often encourage regionalization of supply chains and increased investment in U.S.-based biomanufacturing capacity, strengthening long-term market resilience. Recent policy developments, such as U.S. Commerce Department investigations in 2025 into medical equipment imports (including biomanufacturing-related tools under Section 232 trade reviews), highlight potential future tariff adjustments that could further influence sourcing strategies and encourage domestic production of bioprocessing equipment. Overall, while tariffs may temporarily increase costs and supply chain complexity, they are also accelerating localization trends and reinforcing North America's leadership in advanced bioprocessing technologies, including single-use bioreactors.

How This Analysis Helps Clients

• Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
• Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
• Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
• Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.

Key takeaways from the Single-use Bioreactors market report study

• Market size analysis for the current single-use bioreactors market size (2025), and market forecast for 8 years (2026 to 2034)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the single-use bioreactors market.
• Various opportunities available for the other competitors in the single-use bioreactors market space.
• What are the top-performing segments in 2025? How these segments will perform in 2034?
• Which are the top-performing regions and countries in the current single-use bioreactors market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for the single-use bioreactors market growth in the future.

Frequently Asked Questions for the Single-use Bioreactors Market

1. What is the growth rate of the single-use bioreactors market?

• The single-use bioreactors market is estimated to grow at a CAGR of 17.27% during the forecast period from 2026 to 2034.

2. What is the market for single-use bioreactors?

• The global single-use bioreactors market is expected to increase from USD 3,613.82 million in 2025 to USD 15,114.53 million by 2034.

3. Which region has the highest share in the single-use bioreactors market?

• North America is expected to dominate the single-use bioreactors market due to its strong biopharmaceutical industry, high adoption of advanced bioprocessing technologies, and significant presence of key players such as Thermo Fisher Scientific Inc., Cytiva, and Sartorius AG. The region also benefits from substantial R&D investments, a well-established regulatory framework, and increasing demand for biologics, vaccines, and cell & gene therapies. Additionally, the growing number of CDMOs and biotechnology startups further accelerates the adoption of flexible and cost-effective single-use systems, supporting overall market growth.

4. What are the drivers for the single-use bioreactors market?

• The single-use bioreactors market is being strongly driven by the combined impact of rising demand for biopharmaceuticals, cost efficiency, and technological advancements in bioprocessing. The growing need for biologics such as monoclonal antibodies, vaccines, and cell & gene therapies is increasing the demand for flexible and sterile manufacturing platforms, where single-use systems are highly effective. At the same time, these bioreactors significantly reduce capital investment and operational costs by eliminating cleaning, sterilization, and large infrastructure requirements, making them especially attractive for emerging biotech firms and CDMOs. Additionally, continuous innovations in bioprocessing, such as improved scalability, automation, and advanced sensor integration, are enhancing productivity and process control. Together, these factors are accelerating the adoption of single-use bioreactors across R&D and commercial manufacturing, thereby boosting overall market growth.

5. Who are the key players operating in the single-use bioreactors market?

• Some of the key market players operating in the single-use bioreactors market include Sartorius AG, Thermo Fisher Scientific Inc., Cytiva, Merck KGaA, Eppendorf SE, ABEC Inc., PBS Biotech Inc., Cellexus International Ltd., Celltainer Biotech BV, Getinge AB, Solaris Biotech Solutions S.r.l., Pierre Guerin SAS, Meissner Filtration Products Inc., Entegris Inc., Avantor Inc., Repligen Corporation, Corning Incorporated, and others.